Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05457998 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

BioFINDER-Brown: Examination of Alzheimer's Disease Biomarkers

StatusEnrolling by Invitation
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Recruiting to Enrolling by Invitation
    • Site details revised
    v8
  2. Eligibility criteria revisedv7
  3. Primary and study completion dates: Mar 2028 to Jun 2028
    • Start date changed from estimate of May 2023 to Jun 14, 2023
    v6
  4. Start date: Mar 2023 to May 2023v5
  5. Trial status: Not Yet Recruiting to Recruitingv4 Show 4 more changesShow less
    • Study sites: 0 to 1
    • Primary and study completion dates: Dec 2027 to Mar 2028
    • Start date: Jan 2023 to Mar 2023
    • Interventions: Flutemetamol F18 Injection (Diagnostic Test), [18F]-GTP-1 Injection (Diagnostic Test), [18F]-MK-6240 Injection (Diagnostic Test)… to Flutemetamol F18 Injection (Diagnostic Test), [18F]-MK-6240 Injection (Diagnostic Test), [18F]-RO6958948 Injection (Diagnostic Test)
Show 2 earlier versionsHide 2 earlier versions
  1. Start date: Nov 7, 2022 to Jan 2023
    • Primary and study completion dates: Nov 1, 2027 to Dec 2027
    v3
  2. Start date: Sep 1, 2022 to Nov 7, 2022
    • Primary and study completion dates: Sep 1, 2027 to Nov 1, 2027
    • Eligibility criteria shortened, about 16 words
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Butler Hospital
30 trials monitored
See 1 trial at risk
Dementia
1,978 trials monitored
See 106 trials at risk
Alzheimer's Disease
1,253 trials monitored
See 71 trials at risk
This research study aims to examine biomarkers of Alzheimer's disease as early as possible which could potentially be a screening tool for the general population. This observational study will take place at the Memory and Aging Program at Butler Hospital. The study will enroll up to 200 cognitively healthy subjects aged 50 to 80 years with ongoing recruitment and enrollment for 2 years, and subject participation lasting approximately 4 years. Disclosure of AD risk assessments will be an optional procedure. Two PET imaging sub-studies will also be optional.
Trial Details
NCT Number NCT05457998
Lead Sponsor Butler Hospital
Collaborators: The Warren Alpert Foundation, Brown University, University of Rhode Island, Hoffmann-La Roche, Eli Lilly and Company, GE Healthcare
Conditions
(from sponsor)		 Alzheimer Disease, Mild Cognitive Impairment, Dementia
Related terms Alzheimer Disease, Cognitive Dysfunction, Dementia, Disease, Pick Disease of the Brain
Enrollment 200 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov